Dizon-Townson D, Branch D W
University of Utah School of Medicine, Department of Obstetrics and Gynecology, Salt Lake City 84132, USA.
Semin Thromb Hemost. 1998;24 Suppl 1:55-62.
During pregnancy and the immediate puerperium, the risk for venous thromboembolism (VTE) is substantially increased. Certain medical conditions, including inherited or acquired thrombophilias, and obstetric manipulations such as cesarean delivery further increase this risk. Consequently, acute VTE is one of the leading causes of maternal morbidity and direct mortality in the United States and other developed countries. That considered, clinicians and researchers must understand how to effectively use anticoagulant drugs during pregnancy, and must recognize areas for improvement in the knowledge of these medications. These areas are especially important, because the use of anticoagulants during pregnancy may even increase in light of recent information indicating that thrombophilia is associated with certain more common obstetrical complications.
在孕期及产褥早期，静脉血栓栓塞（VTE）风险大幅增加。某些疾病状况，包括遗传性或获得性易栓症，以及剖宫产等产科操作会进一步增加此风险。因此，急性VTE是美国及其他发达国家孕产妇发病和直接死亡的主要原因之一。鉴于此，临床医生和研究人员必须了解如何在孕期有效使用抗凝药物，并且必须认识到在这些药物知识方面有待改进之处。这些方面尤为重要，因为鉴于最近有信息表明易栓症与某些更常见的产科并发症相关，孕期抗凝剂的使用可能会增加。
